Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

HEU-EFS · HARMONISED APPROACH TO EARLY FEASIBILITY STUDIES FOR MEDICAL DEVICES IN THE EUROPEAN UNION

HORIZONStatus: SIGNED1 October 202330 September 2027EU funding €10,532,198Call HORIZON-JU-IHI-2022-02-two-stage

EU Regulations on medical devices (MDs), in-vitro diagnostics, and Health Technology Assessment envisage a harmonised lifecycle approach for clinical evidence generation of MDs. To be effective this approach requires evidence generation plan to be developed since early stages of product development, by engaging all relevant stakeholders.At present, in the EU there are no standardized procedural frameworks/guidelines/common reference standards for Early Feasibility Studies (EFS), clinical investigations allowed by ISO 14155:2020 conducted early in the development aiming to inform the product development.The ambition of the HEU-EFS project is to develop a harmonised framework for the EU EFS Program, as one integrated step of evidence generation cycle. Project objectives include: (1) conducting research/analysis on state of play (i.e., characteristics, challenges, impacts) of pre-market programs for MDs, including EFS; (2) building a sustainable network of stakeholders at EU/national level to promote/support EFS implementation; (3) developing a sound, widely applicable, harmonised EU methodology and formulating recommendations to uptake EFS; (4) undertaking pilots to test the proposed framework; (5) developing instruments to monitor the EFS performance; and (6) implementing a dedicated, sustainable, open access online portal dedicated to EFS methodological framework, best practices and network.To achieve these goals, the HEU-EFS consortium has been designed including a wide range of relevant stakeholders: research organisations, HTA bodies, patient organizations, healthcare providers, SMEs (including health technology developers, legal experts, and a CRO), and 6 major private companies that are part of a pre-identified industry consortium. An Advisory Board made of competent authorities, notified bodies, medical and biomedical engineering professional associations, networks and industry trade association will collaborate to the success of the initiative.

Consortium · 39 organisations

coordinator

UNIVERSITA COMMERCIALE LUIGI BOCCONI

IT · €3,999,489

thirdParty

EDWARDS LIFESCIENCES GMBH

DE

participant

AGENZIA NAZIONALE PER I SERVIZI SANITARI REGIONALI

IT · €575,380

participant

QURASOFT GMBH

DE · €102,500

participant

FOLKEHELSEINSTITUTTET

NO · €1,087,221

participant

PHILIPPS UNIVERSITAET MARBURG

DE · €626,274

participant

W.L. GORE & ASSOCIATI S.R.L.

IT

thirdParty

ABBOTT LABORATORIES LIMITED

UK

thirdParty

ST JUDE MEDICAL COORDINATION CENTER

BE

thirdParty

ABBOTT FRANCE

FR

participant

CARMAT

FR · €112,500

participant

REGION SYDDANMARK

DK · €313,910

participant

MEDITRIAL S.R.L.

IT · €520,000

participant

FORUM DES PATIENTS EUROPEENS

BE · €329,375

participant

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

IE · €729,880

thirdParty

ABBOTT BV

NL

thirdParty

EDWARDS LIFESCIENCES LLC

US

thirdParty

EVALVE, INC

US

thirdParty

ABBOTT LABORATORIOS LDA

PT

participant

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

FR · €725,494

thirdParty

EDWARDS LIFESCIENCES BV

NL

thirdParty

EDWARDS LIFESCIENCES SAS

FR

participant

NEWRONIKA SPA

IT · €183,125

thirdParty

SOFRADIM PRODUCTION SASU

FR

participant

IDRIS ONCOLOGY B.V.

NL · €68,450

participant

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

ES · €419,484

participant

EDWARDS LIFESCIENCES BELGIUM BV

BE

thirdParty

W L GORE & ASSOCIATES BV

NL

participant

SYNTHES GMBH

CH

thirdParty

ABBOTT GMBH

DE

participant

MEDTRONIC BAKKEN RESEARCH CENTER B.V.

NL

thirdParty

HOSPITAL CLINIC DE BARCELONA

ES

participant

ABBOTT VASCULAR INTERNATIONAL

BE

participant

FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS

IT · €478,500

thirdParty

ST JUDE MEDICAL BUSINESS SERVICES INC

US

participant

GLOBAL HEART HUB COMPANY LIMITED BY GUARANTEE

IE · €260,616

thirdParty

EDWARDS LIFESCIENCES SARL

CH

participant

PHILIPS MEDICAL SYSTEMS NEDERLAND BV

NL

thirdParty

ST JUDE MEDICAL CARDIOLOGY DIVISION INC

US

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.